• Eui Hyun Kim, Junhyung Kim, Cheol Ryong Ku, Eun Jig Lee, and Sun Ho Kim.
• Department of Neurosurgery, Yonsei University College of Medicine, Seoul, Korea.
• Yonsei Med. J. 2023 Aug 1; 64 (8): 489496489-496.

PurposeTreatment with dopamine agonists (DAs) has been the first-line standard treatment for prolactinoma, and surgery has been reserved for drug intolerance and resistance for several decades. We evaluated whether surgery plays a primary role in prolactinoma management.Materials And MethodsWe conducted a retrospective study of 210 prolactinoma patients who had received surgical treatment at our institution. We analyzed the treatment outcomes according to tumor extent, sex, and preoperative DA medication.ResultsOverall hormonal remission was achieved in 164 patients (78.1%), and complete removal was achieved in 194 patients (92.4%). When the tumors were completely removed, the remission rate increased to 84.5%. Anterior pituitary function was normalized or improved in 94.6% of patients, whereas only 4.1% of patients showed worsening of hormone control. Hormonal remission was higher in patients who had not received DA preoperatively than in those who had received preoperative DA treatment. Smaller tumor size (<1 cm), no invasion into the cavernous sinus, and female sex were predictors of good surgical outcomes.ConclusionAlthough DAs remain the first-line standard treatment for prolactinomas, surgery can be an excellent option and should be considered as an alternative primary treatment modality when patients are predicted to achieve a good surgical outcome.© Copyright: Yonsei University College of Medicine 2023.

17 keywords...

hide…